As part of the agreement, Juno gains access to Trianni’s mAb discovery platform, The Trianni Mouse, which was developed using recent advances in DNA synthesis and genomic modification technology, according to Trianni.
Juno will use the mouse model with its proprietary high throughput, single-cell sequencing technology, and direct-to-CAR screening to identify fully-human binders for conversion to chimeric antigen receptors as part of its engineered T cell programs, according to the company.
"The Trianni Mouse offers an in vivo platform for generating a diverse human antibody response to tumor targets of interest," said Hy Levitsky, M.D., Juno's chief scientific officer in a press release.
"We look forward to using the technology to advance our discovery efforts and build more effective, next-generation CAR T cells,” he added.
Financial details were not disclosed.
Trianni and Juno did not respond to a request for comment.